Influenza and COVID-19 vaccine
| Combination of | |
|---|---|
| Influenza vaccine | Vaccine |
| COVID-19 vaccine | Vaccine |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
Influenza and COVID-19 vaccine is a combined messenger RNA vaccine (mRNA) for protection against influenza and COVID-19.[1][2] It contains mRNA molecules that encode the full-length, membrane-bound hemagglutinin glycoproteins of seasonal influenza virus types A (H1N1 and H3N2) and B (Victoria lineage), as well as parts of the SARS-CoV-2 spike protein, namely the membrane-bound, linked N-terminal domain and the receptor-binding domain.[1][2] It is the first combined vaccine against influenza and COVID-19.[1][2]
The most common side effects include injection site pain, fatigue (tiredness), myalgia (muscle pain), arthralgia (joint pain), headache, chills, lymphadenopathy (swollen lymph nodes), nausea/vomiting, and pyrexia (fever).[1][2]
Mcombriax was authorized for medical use in the European Union in April 2026.[1][3]
Medical uses
[edit]The combined influenza vaccine and COVID-19 vaccine is used to provide active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B; and COVID-19 caused by the SARS-CoV-2 virus.[1][2]
Society and culture
[edit]Legal status
[edit]In February 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Mcombriax, intended for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in adults aged 50 years and older.[1][2] Mcombriax was authorized for medical use in the European Union in April 2026.[1][3]
References
[edit]- 1 2 3 4 5 6 7 8 9 "Mcombriax EPAR". European Medicines Agency (EMA). 27 February 2026. Retrieved 4 March 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- 1 2 3 4 5 6 "First combined COVID-19 and influenza vaccine for people 50 years and older". European Medicines Agency (EMA) (Press release). 27 February 2026. Retrieved 4 March 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- 1 2 "Mcombriax PI". Union Register of medicinal products. 21 April 2026. Retrieved 4 June 2026.
Further reading
[edit]- Rudman Spergel AK, Wu I, Deng W, Cardona J, Johnson K, Espinosa-Fernandez I, et al. (June 2025). "Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial". JAMA. 333 (22): 1977–1987. doi:10.1001/jama.2025.5646. PMC 12060023. PMID 40332892.
- Rudman Spergel AK, Henry C, Nachbagauer R, Kaplonek P, Astley E, Avanesov A, et al. (December 2026). "Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults". Human Vaccines & Immunotherapeutics. 22 (1) 2589644. doi:10.1080/21645515.2025.2589644. PMC 12867370. PMID 41627968.
.svg){kind=small}
 | This pharmacology-related article is a stub. You can help Wikipedia by adding missing information. |